## **Core Concept**
The MYD88 L265P mutation is a gain-of-function mutation that leads to the constitutive activation of the NF-κB pathway. This mutation is commonly associated with certain types of lymphomas. MYD88 is an adaptor protein that plays a crucial role in the signaling pathways of most Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R).

## **Why the Correct Answer is Right**
The MYD88 L265P mutation results in the substitution of leucine (L) to proline (P) at position 265 of the MYD88 protein. This mutation leads to the spontaneous activation of the NF-κB pathway, which promotes cell survival and proliferation. The MYD88 L265P mutation is particularly prevalent in Waldenström's macroglobulinemia, a type of non-Hodgkin lymphoma characterized by the accumulation of IgM-producing lymphoplasmacytic cells.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While MYD88 mutations can occur in other conditions, option A is not specified, making it impossible to assess its accuracy directly.
- **Option B:** Similarly, without the specific content of option B, it's not possible to directly address its incorrectness.
- **Option C:** This option is also unspecified, and thus, its potential incorrectness cannot be evaluated.
- **Option D:** Without details, option D's incorrectness remains unassessed.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that the MYD88 L265P mutation is highly prevalent in Waldenström's macroglobulinemia, with approximately 90% of patients with this condition harboring the mutation. This mutation status can be useful in the diagnosis and management of the disease.

## **Correct Answer:** . Waldenström's macroglobulinemia